May 12, 2023 – Seattle, Washington and Guimarães, Portugal – Pluristyx and Stemmatters are excited to announce a new partnership to accelerate the development of induced pluripotent stem cell (iPSC)-derived advanced therapies.
May 2, 2023 - BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa’s genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and
panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology January 12, 2023 – Toronto – Pluristyx and panCELLa today are excited to announce the granting of a patent used in their universal, off-the-shelf, induced pluripotent stem cells (iPSCs). The Great Britain Patent Office on January 4, 2023 issued patent number
MAKING CELL THERAPY SAFE: Cell therapies are largely derived from induced pluripotent cells or embryonic cells and have the potential of reverting back to the original cell state or forming teratomas (tumours). FailSafe® is linked to cell division so if a cell is proliferating it also expresses the safety switch or suicide gene. FailSafe® is
panCELLa FailSafe® Read More »
Professor Clare Parish BBiomedSci, PhD; NHMRC Senior Research Fellow; Stem Cells and Neural Development laboratory; Florey Institute of Neuroscience & Mental Health; The University of Melbourne; Royal Pde, Parkville; Australia, 3010 Live stream of Dr. Parish speaking at the 31th NECTAR ((Network for European CNS Transplantation and Restoration); Session 10 (November10, 2021) panCELLa thanks the
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB
Pluristyx Featured in Labroots Webinar Read More »
August 2, 2022; Seattle Washington: Blood Cell Storage Inc (BCSI), a medical device company whose products help assure the quality of platelet transfusions and help optimize the environment for embryo growth during in vitro fertilization procedures, today announce a grant award from the Advanced Regenerative Manufacturing Institute (armiusa.org) to create An Automated Cell Differentiation Monitoring
Dr. Brian Hawkins, Chief Technology Officer, Pluristyx, shares his thoughts on cell and gene therapy.
Phacilitate - Humans of CGT Read More »
Accelerated Biosciences’ ethically sourced stem cells will be available for clinical product development in Q3 2022 SEATTLE, WA. – APRIL 26, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), today announced they
Improved access to induced pluripotent stem cells for allogeneic cell therapy applications SEATTLE, WA. – JANUARY 20, 2022 – Pluristyx, Inc. Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically-engineered stem cells, today announced they have entered into a manufacturing and
